These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 1981136)

  • 81. Proceedings of the Seventh International Symposium on Advances in Targeted Therapy. April 6-10, 2005. Venice, Italy.
    Ann Rheum Dis; 2005 Nov; 64 Suppl 4():iv1-108. PubMed ID: 16239375
    [No Abstract]   [Full Text] [Related]  

  • 82. Enumeration of IgA producing cells by the enzyme linked immunospot (ELISPOT) technique to evaluate sulphasalazine effects in inflammatory arthritides.
    Feltelius N; Gudmundsson S; Wennersten L; Sjöberg O; Hällgren R; Klareskog L
    Ann Rheum Dis; 1991 Jun; 50(6):369-71. PubMed ID: 1676256
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Side effect profile of 200 patients with inflammatory arthritides treated with sulphasalazine.
    Farr M; Scott DG; Bacon PA
    Drugs; 1986; 32 Suppl 1():49-53. PubMed ID: 2877853
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Sulphasalazine and ankylosing spondylitis: an open pilot study.
    Coelho Andrade LE; Atra E; Bosi Ferraz M
    Clin Exp Rheumatol; 1989; 7(6):661-2. PubMed ID: 2575477
    [No Abstract]   [Full Text] [Related]  

  • 85. Sulphasalazine-induced lupus in psoriatic arthritis.
    Veale DJ; Ho M; Morley KD
    Br J Rheumatol; 1995 Apr; 34(4):383-4. PubMed ID: 7788157
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Rheumatic Manifestations in Patients with Chikungunya Infection.
    Arroyo-Ávila M; Vilá LM
    P R Health Sci J; 2015 Jun; 34(2):71-7. PubMed ID: 26061056
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Is the treatment of inflammatory arthritis different in sickle cell disease?
    Kimyon G; İlhan G
    Turk J Med Sci; 2022 Jun; 52(5):1721-1728. PubMed ID: 36422487
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Bisphosphonates in inflammatory rheumatic diseases.
    Peris P; Monegal A; Guañabens N
    Bone; 2021 May; 146():115887. PubMed ID: 33592328
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Clinical and biochemical study covering 100 treatments with Tolectin.
    J Belge Rhumatol Med Phys; 1976; 31(2):87-93. PubMed ID: 1087309
    [No Abstract]   [Full Text] [Related]  

  • 90. The role of sulphasalazine in African patients with HIV-associated seronegative arthritis.
    Adebajo AO; Mijiyawa M
    Clin Exp Rheumatol; 1998; 16(5):629. PubMed ID: 9779324
    [No Abstract]   [Full Text] [Related]  

  • 91. Update on clinical trials in the rheumatic diseases.
    Furst DE
    Curr Opin Rheumatol; 1998 Mar; 10(2):123-8. PubMed ID: 9567207
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Sulphasalazine for palindromic rheumatism.
    Golding DN
    Br J Rheumatol; 1988 Feb; 27(1):79. PubMed ID: 2892559
    [No Abstract]   [Full Text] [Related]  

  • 93. Prolonged treatment with tolfenamic acid in inflammatory rheumatic diseases.
    Kajander A; Martio J; Mutru O; Gothoni G
    Scand J Rheumatol; 1976; 5(3):158-60. PubMed ID: 1086507
    [TBL] [Abstract][Full Text] [Related]  

  • 94. [Vitamin E in therapy of rheumatic diseases].
    Sangha O; Stucki G
    Z Rheumatol; 1998 Aug; 57(4):207-14. PubMed ID: 9782601
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Sulphasalazine therapy in RA.
    Amos RS; Bax DE; Greaves MS
    Ann Rheum Dis; 1986 May; 45(5):439. PubMed ID: 2872858
    [No Abstract]   [Full Text] [Related]  

  • 96. Sulfasalazine and ankylosing spondylitis.
    Amor B; Kahan A; Dougados M; Delrieu F
    Ann Intern Med; 1984 Dec; 101(6):878. PubMed ID: 6149718
    [No Abstract]   [Full Text] [Related]  

  • 97. [Clinical-psychosomatic aspects in rheumatology].
    Freyberger H; Ritter KH
    Verh Dtsch Ges Rheumatol; 1978; 5():3-7. PubMed ID: 309239
    [No Abstract]   [Full Text] [Related]  

  • 98. Second-line treatment in seronegative spondylarthropathies.
    Creemers MC; van Riel PL; Franssen MJ; van de Putte LB; Gribnau FW
    Semin Arthritis Rheum; 1994 Oct; 24(2):71-81. PubMed ID: 7839156
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Potential bias in Kaplan-Meier survival analysis applied to rheumatology drug studies.
    Utley M; Gallivan S; Young A; Cox N; Davies P; Dixey J; Emery P; Gough A; James D; Prouse P; Williams P; Winfield J; Devlin JA
    Rheumatology (Oxford); 2000 Jan; 39(1):1-2. PubMed ID: 10662865
    [No Abstract]   [Full Text] [Related]  

  • 100. The combined prevalence of classified rare rheumatic diseases is almost double that of ankylosing spondylitis.
    Leyens J; Bender TTA; Mücke M; Stieber C; Kravchenko D; Dernbach C; Seidel MF
    Orphanet J Rare Dis; 2021 Jul; 16(1):326. PubMed ID: 34294115
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.